LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) EBIT

As of the most recent data (March 2024), LSBPW shows a EBIT of $-200M. That compares with $-9.4M in the prior-year period — down 2021.5% year over year. That is below the sector sector average of $-6.4M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LSBPW's EBIT is now $-200M (was $-9.4M) — a 2021.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) is outperforming or lagging.

The its sector sector average EBIT is about $-6.4M. LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) is at $-200M, which is lower that average. That is roughly 3018.9% below the sector mean. Use the comparison chart on this page to see how LSBPW stacks up against individual peers as well.

Tracking LSBPW's ebit over time shows whether LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) is scaling, shrinking, or reshaping that part of the business. The current reading is $-200M That compares with $-9.4M in the prior-year period — down 2021.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-200M) with ownership activity and broader fundamentals.